SAR studies of 9-norbornylpurines as Coxsackievirus B3 inhibitors
Language English Country Great Britain, England Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
21684160
DOI
10.1016/j.bmcl.2011.05.070
PII: S0960-894X(11)00699-8
Knihovny.cz E-resources
- MeSH
- Antiviral Agents chemical synthesis chemistry pharmacology MeSH
- Chlorocebus aethiops MeSH
- Enterovirus drug effects MeSH
- Purines chemical synthesis chemistry pharmacology MeSH
- Vero Cells MeSH
- Structure-Activity Relationship MeSH
- Animals MeSH
- Check Tag
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Antiviral Agents MeSH
- Purines MeSH
Coxsackievirus and related enteroviruses are important human pathogens that cause various diseases with clinical manifestations ranging from trivial flu-like syndromes to dangerous or even fatal diseases such as myocarditis, meningitis and encephalitis. Here, we report on our continuous SAR study focused on 9-(bicyclo[2.2.1]hept-2-yl)-9H-purines as anti-enteroviral inhibitors. The purine moiety was modified at positions 2, 6 and 8. Several analogues inhibited Coxsackievirus B3 as well as other enteroviruses at low-micromolar concentrations. The 6-chloropurine derivative was confirmed as the most active compound in this series.
References provided by Crossref.org
